• Resources
  • About
  • Events
    • Upcoming Events
    • Archived Events
  • The ORBCoN Report
CALL TO ACTION: SUNSETTING OF TTISS/TESS PROGRAMS
  • Bloody Easy E-Tools & Publications
    • Bloody Easy Blood Administration (BEBA)
    • Bloody Easy for Healthcare Professionals
    • Bloody Easy Lite
    • ORBCoN Tech Assess
  • Blood Utilization & Audits
    • Audits Tools
    • Blood Utilization Graphs
    • COPTN Reports
    • O Negative RBC Utilization
    • Provincial Audit Reports
  • IVIG/SCIG
  • Massive Hemorrhage Protocol
    • eLearning
    • Provincial MHP Toolkit
    • Supplementary Resources
    • Recommendation Statements
  • ORBCoN Resources
    • Helpful Apps
    • The ORBCoN Report
    • Order Resources
    • Presentation Library
  • Toolkits
    • Bedside Audit
    • Dispensary and Administration
    • Emergency Blood Management
    • Home Infusion Toolkit
    • Implementing an Evaluation Process for your Transfusion Medicine Lab Competency Assessment Program (CAP)
    • Inventory Management
    • New Product
    • OTTRM
    • Resources for Midwives
    • Special Blood Requirements
    • Transporting Blood Internally
    • Transfusion Committee
    • Transfusion Safety Officer Resource Manual
    • Quality Improvement Plan
  • TM Guidelines, Standards, & Recommendations
    • Guidelines
    • NAC Guidelines and Recommendations
    • Recommendations
    • Resource Manual for Medical Directors of Transfusion Medicine
    • Standards
  • Quality Improvement
Home » IVIG/SCIG » Utilization Management Guidelines »

Parvovirus B19 in solid organ transplant recipients

Do Not Use

For the following indications, there is insufficient or no evidence to support the use of IG. Alternatives to IG are often available.

RecommendationsIG is not recommended to prevent recurrence of parvovirus B19 infection.
 
(see separate entry for established parvovirus B19 infection)
  • Utilization Management Guidelines

    Transplant

    • Community-acquired respiratory virus (CARV), upper respiratory tract infection (URTI) in high-risk patients
    • Community-acquired respiratory virus (CARV), upper respiratory tract infection (URTI)
    • Cytomegalovirus (CMV) infection, prevention
    • Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorders (PTLD)
    • Parvovirus B19 in solid organ transplant recipients – established infection
    • Parvovirus B19 in solid organ transplant recipients
    • Pulmonary graft-versus-host disease
    • Solid organ transplant, active antibody-mediated rejection (ABMR) prevention and management
    • Solid organ transplant, ongoing desensitization, prevention or treatment of graft rejection

© 2025 Copyright: Ontario Regional Blood Coordinating Network

    • Contact
    • Order Resources
    • Careers
    • Useful Links
    • Privacy
    • Legal
Subscribe to our newsletter
    • Contact
    • Order Resources
    • Careers
    • Useful Links
    • Privacy
    • Legal
Subscribe to our newsletter

© 2025 Copyright: Ontario Regional Blood Coordinating Network